Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease.
Infectious agents are possible stimulators of inflammation in atherogenesis. The aim of this study was to investigate if Chlamydia pneumoniae and Helicobacter pylori were associated with elevated levels of tumor necrosis factor alpha (TNFalpha) and interleukin-6 in coronary heart disease (CHD) patients (n=193) and age- and sex-matched controls (n=193) as markers of increased inflammatory activity. C reactive protein (CRP) and fibrinogen were also included. Serologic status towards the two bacteria was measured and levels of the inflammatory markers were compared between seropositives and seronegatives, each study group being evaluated separately. In CHD patients Chlamydia lipopolysaccharide (LPS) IgA seropositivity predicted elevated TNFalpha levels (P=0.009), still statistically significant after adjustment for traditional cardiovascular risk factors (P=0.005). Chlamydia LPS IgG seropositivity independently predicted fibrinogen levels in CHD patients (P=0.028), while no association between serology and inflammatory markers were observed among controls. H. pylori seropositivity alone was not associated with any increase in the inflammatory markers in any of the two groups. However, in CHD patients seropositivity to both agents predicted higher levels of TNFalpha (P=0.041), CRP (P=0.037) and fibrinogen (P=0.001) compared to double seronegativity. We conclude that C. pneumoniae LPS seropositivity may contribute to increased vascular inflammation in CHD patients, possibly even more pronounced when present in combination with H. pylori seropositivity.
Schumacher
A
A
Department of Microbiology and Department of Medicine, Vestfold Central Hospital, PB 2168 Postterminalen, 3103, Tonsberg, Norway. vssmikro@online.no
Seljeflot
I
I
Lerkerød
A B
AB
Sommervoll
L
L
Otterstad
J E
JE
Arnesen
H
H
D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D002690:Chlamydia Infections / Q000097:blood*; D016993:Chlamydophila pneumoniae / Q000276:immunology / Q000302:isolation & purification; D003327:Coronary Disease / Q000097:blood / Q000382:microbiology*; D005260:Female; D016481:Helicobacter Infections / Q000097:blood*; D016480:Helicobacter pylori / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D000907:Antibodies, Bacterial; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein